COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Abatacept Treatment in Polymyositis and Dermatomyositis (ARTEMIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01315938
Recruitment Status : Unknown
Verified February 2010 by Karolinska Institutet.
Recruitment status was:  Recruiting
First Posted : March 16, 2011
Last Update Posted : March 16, 2011
Institute of Rheumatology, Prague, Czech Republic
King's College Hospital NHS Trust
Information provided by:
Karolinska Institutet

Brief Summary:
The purpose of this study is to investigate the clinical efficacy of abatacept on disease activity in polymyositis, and dermatomyositis patients.

Condition or disease Intervention/treatment Phase
Polymyositis Dermatomyositis Drug: Abatacept Phase 2

Detailed Description:
Patients with polymyositis or dermatomyositis who have persisting signs of inflammatory active disease after treatment with glucocorticoids and at least one immunomodulating drug (e.g. methotrexate or azathioprine) for a minimum of 3 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Abatacept Treatment in Polymyositis and Dermatomyositis
Study Start Date : January 2011
Estimated Primary Completion Date : December 2012
Estimated Study Completion Date : June 2013

Arm Intervention/treatment
Experimental: Abatacept Drug: Abatacept
abatacept will be given as intravenous infusions at time 0 then after, 2, 4, 8, 12, 16 and 20 weeks.

Drug: Abatacept
Subjects will be treated with abatacept for 6 months and receive a total of up to 7 doses (intravenous infusions) the infusions will be given with the following intervals: at time 0 then after, 2, 4, 8, 12, 16 and 20 weeks.

Primary Outcome Measures :
  1. The number of responders, defined as improved according the IMACS criteria [ Time Frame: 6 months ]
    The definition of improvement is based on a core set of clinical and laboratory variables to assess disease activity and outcome measure developed in an international consensus, partly validated and recommended for use in clinical trials by the IMACS group (26 The improvement is defined as any 3 of 6 core set measures improved ≥ 20% with no more than 2 (not including MMT) worse by ≥ 25%.

Secondary Outcome Measures :
  1. The change in the individual components of the IMACS core set measures for disease activity [ Time Frame: at 3 and 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with definite or probable polymyositis or dermatomyositis diagnosed according to the diagnostic criteria by Bohan and Peter (30,31).
  2. For polymyositis a muscle biopsy is required that confirmed this disease (performed at any time before the start of the study) and to exclude other conditions unless a patient is positive for myositis specific or myositis associated autoantibodies.
  3. Polymyositis will be included after a judicial process by the three PIs.
  4. Inflammatory active disease based on persisting or worsening muscle weakness, MMT < 150 or low endurance, FI -2 < 20% of upper value together with at least one other sign of active disease: elevated serum levels of muscle enzymes (CK, LD, ASAT, ALAT, above upper limit and being explained by muscle involvement and not eg liver disease), inflammation in recent muscle biopsy (< 3 months) or on MRI scans or active extramuscular disease: skin rash, arthritis or interstitial lung disease (ILD) (as suggested by chest X-ray, high resolution computerized tomography (HRCT), or pulmonary function test).
  5. Persisting disease activity after a minimum of 3 months treatment with prednisolone or equal drug. The treatment with prednisolone (or equal) should include the dose of at least 0.5 mg/kg/day for at least 1 month in the history and should be stable 1 month prior the baseline visit. Maximum dose of glucocorticoids should not exceed the equivalent of Prednisone 30 mg per day at the time of randomisation.
  6. Combination with at least one other immunosuppressive drug, which includes methotrexate (minimum dose 15 mg/week) or azathioprine (minimum dose 100 mg/day) for at least 3 months. The dose of methotrexate or azathioprine should be stable for at least 1 month before the first administration of abatacept.
  7. If methotrexate or azathioprine has had to be stopped or the dose decreased due to documented intolerance, lower dose or absence of these drugs is accepted provided this situation is stable for 1 month before the baseline.
  8. Age between 18 - 80 years.
  9. Signed informed consent.


Exclusion Criteria:

  1. Patients with other types of inflammatory myopathies including

    • Drug induced myositis.
    • Inclusion body myositis
    • Malignancy associated myositis.
  2. Women who are pregnant or breastfeeding.
  3. Women with a positive pregnancy test on enrolment or prior to start of study drug administration.
  4. Women of Child Bearing age who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for 10 weeks after the last infusion of study medication.
  5. Current symptoms of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, neurological, ophthalmologic or cerebral disease with the exception of those symptoms that are a manifestation of polymyositis or dermatomyositis. Concomitant medical conditions that in the opinion of the investigator might place the subject at unacceptable risk for participation in this study.
  6. Subjects with a history of cancer within the last five years (other than non-melanoma skin cell cancers cured by local resection). Existing non-melanoma skin cell cancers must be removed prior to dosing. Patients with dermatomyositis need to be screened for malignancies according to routine procedures.
  7. Subjects who have a history of clinically significant drug or alcohol abuse. Subjects currently taking methotrexate who admit to consumption of more than an average of 1 alcoholic drink per day.
  8. Subjects with any serious bacterial infection (such as pneumonia, other renal infection and sinusitis), unless treated and resolved with antibiotics or chronic bacterial infection (such as pyelonephritis and chest infection with bronchiectasis) in the previous 3 months.
  9. Subjects with active tuberculosis requiring treatment within the previous 3 years. Subjects with a positive PPD at screening will not be eligible for the study unless they completed treatment for latent TB and have a negative chest x-ray at enrolment. A PPD response that is equal to or greater than 10 mm should be considered a positive test, although more conservative criteria may be applied as determined by the clinical circumstance and investigator according to published guidelines and/or local standards endorsed by the medical society. Quantiferon assay may replace PPD testing and patients are excluded from the study if the test is positive. Quantiferon positive patients who completed treatment for latent tuberculosis according to the local guidelines may be considered for enrolment.
  10. Subjects with herpes zoster that resolved less than 2 months prior to enrolment.
  11. Subjects with evidence (as assessed by the Investigator) of active or latent bacterial or viral infections at the time of potential enrolment, including subjects with evidence of Human Immunodeficiency Virus (HIV) infection.
  12. Significant toxicities associated with concomitant or previous immunosuppressive Therapy and anti-TNF therapy that would preclude subjects from participating and completing the study
  13. Patients with clinically apparent immunodeficiency syndrome, (IgA deficiency alone is not an exclusion criterion)
  14. Subjects with any of the following laboratory values:

    • Hgb < 8.5 g/dL.
    • WBC < 3,000/mm3 (3 x 109/L).
    • Platelets < 100,000/mm3 (100 x 109/L).
    • Serum creatinine > 2 times upper limit of normal.
    • Any other laboratory test results that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study.
  15. Subjects previously treated with rituximab: B cell levels are less than lower limit of normal as measured by Fluorescent Activated Cell Sorting (FACS) analysis.
  16. For all patients who have received prior rituximab, a normal CD19 B cell count must be documented at the time of screening for this study.
  17. Patients with Large granular lymphocyte (LGL) syndrome (to minimize the risk of including patients with high frequency of CD28 null T cells) that may not benefit from treatment.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01315938

Layout table for location contacts
Contact: Ingrid E Lundberg, MD, PhD +46851770000 ext 6087
Contact: Maryam Dastmalchi, MD; PhD +46851770000 ext 1915

Layout table for location information
Czech Republic
Institute of Rheumatology Not yet recruiting
Prague, Czech Republic, 12850
Contact: Jiri Vencovsky, MD, PhD    +420224914469   
Contact: Herman Mann, MD   
Principal Investigator: Jiri Vencovsky, MD;PhD         
Sub-Investigator: Herman Mann, MD         
Karolinska University Hospital Recruiting
Stockholm, Sweden, 17176
Contact: Ingrid E Lundberg, MD, PhD    +46851770000 ext 6087   
Contact: Maryam Dastmalchi, MD, PhD    +46851770000 ext 1915   
Principal Investigator: Ingrid E Lundberg, MD,PhD         
Sub-Investigator: Maryam Dastmalchi, MD,PhD         
Sponsors and Collaborators
Karolinska Institutet
Institute of Rheumatology, Prague, Czech Republic
King's College Hospital NHS Trust
Layout table for additonal information
Responsible Party: Ingrid E. Lundberg, Karolinska Institutet Identifier: NCT01315938    
Other Study ID Numbers: 2009-015957-20
First Posted: March 16, 2011    Key Record Dates
Last Update Posted: March 16, 2011
Last Verified: February 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Connective Tissue Diseases
Skin Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents